Understanding how certain genetic changes lead to advanced stomach cancer
Official title: Mechanisms of CDH1-inactivated advanced gastric adenocarcinoma tumorigenesis
Funded at University of Tx Md Anderson Can Ctr · NIH-11052790 · Data updated 2026-11-12
This study is looking into how a specific gene called CDH1 affects the growth of advanced stomach cancer, with the hope of finding better treatment options tailored to different types of the disease, so that patients can receive care that works best for them.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | February 1, 2025 |
| Project end | January 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $125,783 |
| NIH project number | 1K99CA286745-01A1 |
| Project ID | NIH-11052790 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with advanced gastric adenocarcinoma, particularly those with CDH1 inactivation.
✕Less likely to help
Patients with early-stage gastric cancer or those whose tumors do not involve CDH1 inactivation may not benefit from this research.
What this research studies
This research investigates the mechanisms behind advanced gastric adenocarcinoma (GAC), particularly focusing on the role of the CDH1 gene in tumor development. By identifying specific subtypes of GAC, the study aims to stratify patients for tailored treatments based on their tumor characteristics. The researchers utilize advanced techniques, including murine organoid models and genetic engineering, to explore how these tumors grow and respond to therapies. The goal is to uncover unique immune profiles and potential therapeutic targets that could improve patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to more effective, personalized treatment options for patients with advanced gastric cancer.
How similar studies have gone: Previous research has shown promise in targeting specific genetic alterations in cancer, suggesting that this approach could yield significant insights and advancements.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Zou, Gengyi — University of Tx Md Anderson Can Ctr
- Study coordinator: Zou, Gengyi
Related research
Other NIH-funded projects on the same topics.
-
Understanding how CDH1 loss drives aggressive stomach cancer and how to target it
Researchers are studying why certain advanced stomach cancers grow and spread, with a focus on CDH1 inactivation and related pathways to find ways to improve treatment for patients.
-
Common stem cell origin in Barrett's-related cancers
This research looks at whether a single stem cell type drives both esophageal and gastric cancers that arise from Barrett’s esophagus, with the aim of finding shared clues to prevent or treat these diseases.
-
Shared stem cell source for lower esophagus and upper stomach cancers
This project looks at whether the same type of stem cell drives cancers that start in Barrett's esophagus and the nearby stomach, with implications for people who have Barrett's esophagus or gastric intestinal metaplasia.
-
Targeting YAP1 to stop stomach cancer spread and immune suppression
This project looks for ways to block a protein called YAP1 to help people with advanced stomach (gastric) cancer that has spread to the lining of the abdomen.
-
Understanding and targeting cancer stemness and immune suppression in advanced gastric cancer
This study is looking at how a protein called YAP1 affects advanced stomach cancer, especially in patients with cancer that has spread to the lining of the abdomen, to find new ways to treat this tough condition and help improve outcomes for patients.
-
Investigating the common origin of esophageal and gastric cancers
This study is looking into how esophageal adenocarcinoma and intestinal gastric cancer start and develop, aiming to find early warning signs and better treatments for people dealing with these cancers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.